News >

FDA Approves Acalabrutinib for Mantle Cell Lymphoma

Silas Inman @silasinman
Published: Tuesday, Oct 31, 2017

Richard Pazdur, MD
Richard Pazdur, MD
The FDA has granted an accelerated approval to acalabrutinib (Calquence) as a treatment for adult patients with mantle cell lymphoma (MCL) following at least 1 prior therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication